Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001558370-25-005563
Filing Date
2025-04-25
Accepted
2025-04-25 16:25:31
Documents
18
Period of Report
2025-06-03

Document Format Files

Seq Description Document Type Size
1 DEF 14A fencf-20250603xdef14a.htm   iXBRL DEF 14A 1345510
2 GRAPHIC fencf-20250603xdef14a_a003.jpg GRAPHIC 81079
3 GRAPHIC fencf-20250603xdef14a_bg001.jpg GRAPHIC 120115
4 GRAPHIC fencf-20250603xdef14a_bg002.jpg GRAPHIC 115610
  Complete submission text file 0001558370-25-005563.txt   3264456

Data Files

Seq Description Document Type Size
5 EX-101.SCH fencf-20250603.xsd EX-101.SCH 4386
6 EX-101.DEF fencf-20250603_def.xml EX-101.DEF 3064
7 EX-101.LAB fencf-20250603_lab.xml EX-101.LAB 6263
8 EX-101.PRE fencf-20250603_pre.xml EX-101.PRE 5203
20 EXTRACTED XBRL INSTANCE DOCUMENT fencf-20250603xdef14a_htm.xml XML 400545
Mailing Address PO BOX 13628 68 TW ALEXANDER DRIVE RESEARCH TRIANGLE PARK NC 27709
Business Address PO BOX 13628 68 TW ALEXANDER DRIVE RESEARCH TRIANGLE PARK NC 27709 (919) 636-4530
FENNEC PHARMACEUTICALS INC. (Filer) CIK: 0001211583 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-32295 | Film No.: 25874503
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)